Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Adam Eckert

Why Athira Pharma Stock Is Plunging

Athira Pharma Inc (NASDAQ:ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease.

Athira said the primary endpoint of change in biomarker ERP P300 latency was not statistically significant in the study.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.